197 related articles for article (PubMed ID: 8783582)
21. Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities.
Jönsson PE; Hafström L; Hugander A
Recent Results Cancer Res; 1983; 86():277-82. PubMed ID: 6648009
[No Abstract] [Full Text] [Related]
22. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
[TBL] [Abstract][Full Text] [Related]
23. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion.
Coit DG
Cancer J Sci Am; 1995; 1(2):104-5. PubMed ID: 9166460
[No Abstract] [Full Text] [Related]
24. Isolated limb perfusion for melanoma.
Kroon BB; Noorda EM; Vrouenraets BC; Nieweg OE
J Surg Oncol; 2002 Apr; 79(4):252-5. PubMed ID: 11920783
[No Abstract] [Full Text] [Related]
25. TNF-based limb perfusion for cutaneous melanoma in transit metastases: suggestions for modification of the perfusional schedule.
Rossi CR; Foletto M; Mocellin S; Pilati PL; Campana L; Rubello D; Lise M
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):103-7. PubMed ID: 16767915
[TBL] [Abstract][Full Text] [Related]
26. Regional therapies for in-transit disease.
Speicher PJ; Meriwether CH; Tyler DS
Surg Oncol Clin N Am; 2015 Apr; 24(2):309-22. PubMed ID: 25769714
[TBL] [Abstract][Full Text] [Related]
27. The use of isolated limb perfusion to manage recurrent malignant melanoma.
Ma D; Ariyan S
Clin Plast Surg; 2000 Jul; 27(3):441-50, ix. PubMed ID: 10941564
[TBL] [Abstract][Full Text] [Related]
28. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
[TBL] [Abstract][Full Text] [Related]
29. Isolation-perfusion: a valuable alternative in managing locally recurrent and in-transit melanoma.
Norvell ST; Bodurtha AJ
Can J Surg; 1983 Jan; 26(1):8. PubMed ID: 6821770
[No Abstract] [Full Text] [Related]
30. In-transit melanoma: an individualized approach.
Grotz TE; Mansfield AS; Kottschade LA; Erickson LA; Otley CC; Markovic SN; Jakub JW
Oncology (Williston Park); 2011 Dec; 25(14):1340-8. PubMed ID: 22329185
[TBL] [Abstract][Full Text] [Related]
31. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
[TBL] [Abstract][Full Text] [Related]
32. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
[TBL] [Abstract][Full Text] [Related]
33. Surgical treatment options for stage IV melanoma.
Wei IH; Healy MA; Wong SL
Surg Clin North Am; 2014 Oct; 94(5):1075-89, ix. PubMed ID: 25245969
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous melanoma metastases.
Lee JE; Mansfield PF; Ross MI
N Engl J Med; 1998 Mar; 338(13):922-3. PubMed ID: 9518292
[No Abstract] [Full Text] [Related]
36. [Is interleukin 2 useful in oncology?].
Négrier S
Rev Prat; 1998 Feb; 48(3):237-9. PubMed ID: 9781067
[No Abstract] [Full Text] [Related]
37. Isolated limb perfusion for melanoma.
Kroon BB; Noorda EM; Vrouenraets BC; van Slooten GW; Nieweg OE
Surg Oncol Clin N Am; 2008 Oct; 17(4):785-94, viii-ix. PubMed ID: 18722918
[TBL] [Abstract][Full Text] [Related]
38. Relapse after successful treatment with immunotherapy: lessons for the future.
Fisher RI
Cancer J Sci Am; 1998; 4(2):78-9. PubMed ID: 9532407
[No Abstract] [Full Text] [Related]
39. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
Richtig E; Ludwig R; Kerl H; Smolle J
Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
[TBL] [Abstract][Full Text] [Related]
40. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma.
Dummer R; Panizzon R; Bloch PH; Burg G;
Dermatology; 2005; 210(1):39-44. PubMed ID: 15604544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
